Troponin I Elevation after Elective Percutaneous Coronary Interventions: Prevalence and Risk Factors

A Dev1, P K Das, B Bhattacharjee

  • 1Dr Alock Dev, Resident, Department of Cardiology, Chattogram Medical College (CMC), Chattogram, Bangladesh;

Insights

Minor elevations in cardiac troponin I (cTnI) are common after percutaneous coronary intervention (PCI). This peri-procedural myocardial injury is associated with factors like older age, renal insufficiency, and multi-vessel stenting.

Area of Science:

  • Cardiology
  • Biochemistry

Background:

  • Percutaneous coronary intervention (PCI) is a primary treatment for coronary artery disease (CAD).
  • Peri-procedural myocardial injury, even after successful PCI, can diminish its benefits.
  • Understanding post-procedural cardiac troponin I (cTnI) elevation is crucial for optimizing PCI outcomes.

Purpose of the Study:

  • To determine the prevalence of elevated cTnI after elective PCI.
  • To identify risk factors associated with post-procedural cTnI elevation.
  • To explore the relationship between cTnI levels and factors like age, BMI, smoking, diabetes, hypertension, dyslipidemia, family history, left ventricular dysfunction, renal insufficiency, and stent characteristics.

Main Methods:

  • A hospital-based observational study involving 50 patients undergoing elective PCI.
  • Serum cTnI levels measured before and 24 hours after PCI using FIA8000 analyzer.
  • Statistical analysis, including univariate and multivariate analysis, to assess predictors of cTnI elevation (>1.0 ng/ml).

Main Results:

  • Eighteen patients (36.0%) showed post-procedural cTnI elevation; 8 (16.0%) had significant elevation (>1.0 ng/ml).
  • The change in cTnI from baseline to 24 hours was not statistically significant (p=0.057).
  • Elevated cTnI was significantly associated with older age (>50 years), elevated pre-procedural serum creatinine, and multi-vessel stenting.

Conclusions:

  • Minor cTnI elevation is a frequent occurrence following elective PCI.
  • Risk factors for this elevation include advanced age, impaired renal function, and the extent of coronary stenting.
  • Early identification and management of these risk factors may help mitigate cardiac tissue injury and cTnI elevation post-PCI.

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
32
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
10
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
21
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
203
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
72
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
12